Loading...
Scandinavian Medical Solutions
powered by Stokk.io

Q2 2024 Presentation and Q&A

Tue, 21 May, 2024, 10:00 – 11:00
This event has ended. Sign up below to watch the recording.
Sign in to access all the features of the platform.

How does this Q&A work:

This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.

The company will address as many questions as possible, and focus on those questions most wanted by investors.

Speakers at this event:

Martin Lind
Head of Sales
Jens Paulsen
CEO
Jens Krohn
CEO US & Founder

8 Questions

S
S**** *****
May 21, 2024

When you say on rental, that you are not at full utilization yet, can you say anything about what level you are at, 80%, 90% or what level?

A
A**** *****
May 21, 2024

Do you have an expected ramp up time in the US before you believe the department is fully operating and profitable as a stand alone department?

A
A**** *****
May 20, 2024

Would you expect that the times of growth rates above 30% is over for now, or is it possible to achieve these levels again once US has been established?

M
Mikkel Kirkegaard Petersen
May 16, 2024

Yout net cash is DKK -15,245 mio. One could expect that opening in US would be an additional drag on cash. Would you consider raising more equity?

M
Mikkel Kirkegaard Petersen
May 16, 2024

You EBITDA-margin has been on a gradual decline since 20/21 (15%) and ended last financial year at 11%, which was also lower than your mid point guidance during the year. What is the main drive in the decreasing margin and also the lower than guided margin and should we expect to see a margin pick up in 24/25?

M
Mikkel Kirkegaard Petersen
May 16, 2024

Your gross profit margin has fluctuated between 14,4% and 23% in your semi anual reports ending at 17% in this H1. Could you give some comments on where you expect to see a normalised gross profit margin going forward? Should we look in the low end of the historic numbers or in the higher end or somewhere in the middle?

M
Mikkel Kirkegaard Petersen
May 16, 2024

You state that "key investments" has had a negative impact on EBITDA in H1. Can you quantify how big the impact is from the ERP system and the US start up costs, and addtionally provide insights in where in the P/L these costs are included?

M
Mikkel Kirkegaard Petersen
May 16, 2024

1. How many FTE wat employeed at the end of H1. You state the average number to be 25, and you normally also state the end of period number, but it seems like it is not included in this report.

2. How many FTE do you expect to be at year end?